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Abstract
Background Pixantrone is recommended in relapsed and
refractory non-Hodgkin lymphoma (NHL) or heavily pre-
treated NHL patients. Its conditional approval in Europe
was based on results from the open-label, randomized,
phase 3 PIX301 study, comparing pixantrone monotherapy
with physician’s choice of treatment in 140 patients with
relapsed or refractory aggressive NHL.
Methods This post-hoc analysis of the PIX301 study
investigated possible correlations between patient charac-
teristics and clinical response in 17 patients (24%) treated
with pixantrone who achieved a complete response (CR) or
an unconfirmed complete response (CRu) at study end.
Results These patients (10 male and 7 female) had a
median age of 61 (range 41–75) years, and the most
common diagnoses were diffuse large B-cell lymphoma
(n = 10) and transformed indolent lymphoma (n = 4).
Most had received two prior lines of therapy (n = 12).
There was wide variation in the time from diagnosis to
study entry (219–4777 days). Among the 17 patients who
achieved a CR/CRu with pixantrone, 6 had stable or pro-
gressive disease as a response to their last regimen, 7 had a
partial response, and 4 had a CR/CRu. Four patients from
the pixantrone group survived without progression for
more than 400 days. Prior response to previous therapies
did not appear to affect long-term response to pixantrone.
Conclusions These observations suggest that pixantrone
monotherapy in patients with multiply relapsed or refrac-
tory aggressive NHL who had received at least two prior
therapies can be associated with durable responses and
long-term remission, and this may be unrelated to the
clinical response to the last therapy.
Key Points
In the PIX301 study, patients with relapsed/
refractory non-Hodgkin lymphoma who achieved a
complete response with pixantrone had various
responses to prior therapies (complete or partial
response, stable or progressive disease).
Four patients receiving pixantrone who had
previously had a complete or partial response (n = 1
each) or progressive disease (n = 2) with prior
therapies, were free from progression for more than
400 days.
These results suggest that pixantrone monotherapy
can induce durable responses and long-term
remission in some patients with relapsed/refractory
non-Hodgkin lymphoma. These responses appear
unrelated to the response to prior therapies.
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1 Introduction
Current management of relapsed/refractory non-Hodgkin
lymphoma (NHL) remains an unmet medical need, due to a
poor prognostic outlook and lack of treatment options [1].
First-line therapy for aggressive B-cell NHL is an anthra-
cycline-based regimen in combination with rituximab, such
as R-CHOP (rituximab, cyclophosphamide, doxorubicin,
vincristine and prednisolone) [2–4]. Complete response
rates with R-CHOP of around 80% have been reported,
with a 5-year progression-free survival (PFS) of approxi-
mately 50% [5]. However, up to 25% of patients inevitably
relapse [6].
Due to the risk of cardiotoxicity with increasing
cumulative anthracycline dose, repeated use of anthracy-
clines is limited in patients with relapsed/refractory disease
[7, 8]. Newer agents are few, and include ibrutinib for
relapsed/refractory mantle-cell lymphoma [9] and idelal-
isib for refractory follicular lymphoma [10]. Pixantrone, an
agent that belongs to the aza-anthracenedione family
[1, 11], is a recommended option in multiply relapsed and
refractory disease or heavily pretreated patients with NHL
[3, 12]. Pixantrone’s molecular structure is different from
anthracyclines [1, 13, 14]. The differences in its structure
result in a unique mechanism of action, notably with a
lesser potential for iron binding and therefore less car-
diotoxicity compared with anthracyclines [1, 11].
Pixantrone has conditional approval in Europe [11],
based on results from the open-label, randomized phase 3
PIX301 study [15, 16], where significantly more patients
who received pixantrone than comparator (physician’s
choice of treatment) achieved a complete (CR) or an
unconfirmed complete response (CRu) and a higher overall
response rate (ORR) [15]; median PFS was also signifi-
cantly prolonged in the pixantrone arm. It is indicated as
monotherapy for the treatment of adult patients with mul-
tiply relapsed or refractory aggressive B-cell NHL [11]. To
complete post-authorization measures, a confirmatory
phase 3 study (PIX306) is underway [15]. Study recruit-
ment is complete and results from the primary efficacy
endpoint analysis are expected in 2018.
There were several cases of long-term remission in the
PIX301 study, including a case of a very durable partial
response (PR) with pixantrone in a patient with relapsed
diffuse large B-cell lymphoma (DLBCL) at study entry
(see Box 1), in addition to some patients with durable CRs.
In the current post-hoc analysis of data from the PIX301
trial, we explored possible correlations between patient
characteristics and clinical response in these cases.
2 Methods
2.1 PIX301 Trial Study Design
The design and methods of the phase 3 PIX301 study have
been described previously [15]. Briefly, PIX301 was a
multicenter, open-label, randomized trial [15]. A total of
140 patients were enrolled in 66 hospital centers in Europe,
India, Russia, South America, UK and USA between
October 2004 and March 2008. All patients provided
written informed consent, and local ethical approval was
obtained in all centers. The study was registered at Clini-
calTrials.gov (NCT00088530).
Enrolled patients were those with aggressive de novo or
transformed NHL, who had relapsed or were refractory to
at least two previous multi-agent chemotherapy regimens,
with previous therapy including at least one standard
anthracycline-based regimen with a response of at least
24 weeks. During the course of the study, the protocol was
amended to exclude patients with no previous treatment
with rituximab in countries where it was commercially
available [15, 16]. Patients also had to have a European
Cooperative Oncology Group performance status of 0–2,
measurable disease, a left ventricular ejection fraction of at
least 50%, adequate bone marrow and organ function and
no persisting toxicities from previous lines of treatment.
Patients were excluded if they had received a cumulative
dose of doxorubicin or equivalent exceeding 450 mg/m2,
or if they had New York Heart Association grade 3 or 4
cardiovascular abnormalities [15].
Patients were randomized (1:1) to receive pixantrone
dimaleate 85 mg/m2 (equivalent to 50 mg/m2 in the base
formulation approved by the European regulatory authori-
ties) by intravenous infusion over 1 h on days 1, 8 and 15
every 28 days for up to six cycles or a comparator agent
[15]. The choice of comparator was left to the treating
physician, but suitable choices included vinorelbine,
oxaliplatin, ifosfamide, etoposide, mitoxantrone, gemc-
itabine or rituximab administered at prespecified standard
doses and schedules. Randomization was achieved by an
interactive voice response system and was stratified by
region (USA vs Western Europe vs the rest of the world),
International Prognostic Index score (0 or 1 vs C 2), and
previous autologous stem-cell transplant (SCT) [yes vs no]
[15]. Patients were followed for 18 months after the last
treatment administration for disease progression and sur-
vival [15].
2.2 Post-Hoc Study Design
This post-hoc analysis included only patients with a CR or
CRu to pixantrone during the PIX301 study in the
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intention-to-treat population. Potential relationships
between patient characteristics, previous therapies and
response to pixantrone were assessed. Additionally, patient
characteristics of long-term responders to pixantrone were
explored.
2.3 Statistical Methods
This study used descriptive statistics only. Values are
presented as means (standard deviation [SD]), medians
(range) or numbers (percentages).
3 Results
3.1 Patients
Overall, 17 patients treated with pixantrone in the inten-
tion-to-treat population achieved a CR/CRu in the PIX301
trial (i.e. 24% of the pixantrone treatment arm). Demo-
graphics and clinical characteristics of these patients are
shown in Table 1. The median age of these patients was 61
(range 41–75) years, and there were slightly more male
than female patients (10 vs 7 patients). The most common
diagnoses were DLBCL (10 patients) and transformed
indolent lymphoma (4 patients). Most patients had received
two prior lines of therapy (12 patients, 71%). Of note, there
was wide variation in the time from diagnosis to study
entry (219–4777 days). Two protocol violations were
subsequently identified, where two patients had received
monotherapy in the treatment line prior to randomization
(Table 2).
3.2 Exploration of Patient Characteristics, Previous
Therapy and Response to Pixantrone
Among the 17 patients who achieved a CR/CRu with
pixantrone, 6 had stable disease or progressive disease
(PD) as a response to their prior regimen, 7 had a partial
response (PR), and 4 had a CR/CRu (Table 2). The
achievement of a durable response with pixantrone there-
fore appeared to be independent of the type of response to
prior therapy (CR, PR, or stable disease).
3.3 Characteristics of Patients with Durable
Responses to Pixantrone
Four patients survived without progression for more than
400 days (Table 2 and Fig. 1). These patients had a dura-
tion of response to pixantrone of 679, 633, 623 and
448 days; respective ages were 75, 60, 63 and 58 years;
respective histologies were DLBCL, DLBCL, transformed
indolent lymphoma and transformed indolent lymphoma;
and respective numbers of prior lines of therapy were two,
two, two and three. The patient with the longest response
duration to pixantrone was the only one of the four patients
to have received prior rituximab treatment. Response to
prior chemotherapy did not appear to affect the long-term
response to pixantrone. Respective last therapies (response;
duration of treatment) prior to pixantrone were R-CHOP
(CR; 67 days); DHAP (cytarabine, dexamethasone, cis-
platin) [PD; 43 days]; ICE (ifosfamide, carboplatin, eto-
poside) [PD; 43 days]; and ESHAP (etoposide,
methylprednisolone, cytarabine, cisplatin) [PR; 96 days].
4 Discussion
At the end of treatment in the main PIX301 study [15],
significantly more patients who received pixantrone
achieved a CR/CRu (20.0 vs 5.7%; p = 0.021) and an
ORR (37.1 vs 14.3%; p = 0.003) than did those who
received a comparator drug. Median PFS was also signif-
icantly prolonged in the pixantrone treatment group [5.3 vs
2.6 months; hazard ratio (HR) 0.60; 95% CI 0.42, 0.86;
p = 0.005]. A post-hoc analysis of data from a subgroup of
Table 1 Demographics and characteristics of the 17 patients with a
CR/CRu with pixantrone
Characteristic Value
Age, years
Median (range) 61 (41–75)
Mean (SD) 61.4 (9.6)
Sex, n (%)
Male 10 (58.8)
Female 7 (41.2)
Diagnosis, n (%)
DLBCL 10 (58.8)
Transformed indolent lymphoma 4 (23.5)
Peripheral T-cell lymphoma NOS 1 (5.9)
Anaplastic large cell lymphoma 1 (5.9)
Follicular lymphoma 1 (5.9)
Prior CT scan, n (%) 1 (5.9)
Previous lines of therapy, n (%)
2 12 (70.6)
3 4 (23.5)
C 4 1 (5.9)
Time from diagnosis to study entry, days
Median (range) 798 (219–4777)
Mean (SD) 1226.0 (1101.3)
CR complete response, CRu unconfirmed complete response, CT
computed tomography, DLBCL diffuse large B-cell lymphoma, NOS
not otherwise specified, SD standard deviation
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patients in the study with histologically confirmed relapsed
or refractory aggressive B-cell NHL also demonstrated a
significantly improved CR/CRu (23.1 vs 5.1%; p = 0.047)
and ORR (43.6 vs 12.8%; p = 0.005) with third- or fourth-
line pixantrone treatment compared with comparator
agents [16]. Clinical response was especially improved
Table 2 Previous therapy received by the 17 patients with a CR/CRu
Patient
number
Prior regimen Duration of prior
regimen, days
Response to
last regimen
Time between end of last regimen
and initiation of pixantrone, days
Duration of response
to pixantrone, days
1 Rituximab plus etoposide,
carmustine,
methylprednisolone
114 PR 506 121
2 R-CHOP 67 CR 637 679
3 Chlorambucila 99 Stable disease 238 18
4 R-DHAP 202 Stable disease 512 151
5 Cytarabine, dexamethasone,
ifosfamide
3 PD 53 213
6 ICE 117 CR 249 56
7 ICE 28 PD 54 623
8 Cytarabine, dexamethasone,
cisplatin
43 PD 226 633
9 CVP 90 PR 2043 1b
10 CVP 47 PR 1108 63
11 ESHAP 96 PR 275 448
12 Rituximab plus cytarabine,
dexamethasone, carboplatin
115 CRu 602 308
13 R-CHOP 107 CR 354 166
14 Dexamethasone, gemcitabine 229 PR 335 80
15 CVP 109 PR 622 82
16 R-ESHAP 105 PR 171 333
17 Cyclophosphamidea 5 Stable disease 50 291
CR complete response, CRu unconfirmed complete response, CVP cyclophosphamide, vincristine, prednisone, ESHAP cytarabine, dexam-
ethasone, cisplatin, etoposide, ICE ifosfamide, carboplatin, etoposide, PD progressive disease, PR partial response, R-CHOP rituximab plus
cyclophosphamide, doxorubicin, vincristine, prednisone, R-DHAP rituximab plus dexamethasone, high-dose cytarabine, cisplatin, R-ESHAP
rituximab plus etoposide, methylprednisolone, high-dose cytarabine, cisplatin
aProtocol violation due to monotherapy as previous therapy
bPatient censored without a true progression or death
Fig. 1 Duration of best
response (from onset of a CR/
CRu to last confirmation of non-
progression). CR complete
response, CRu unconfirmed
complete response. Asterisk:
Censored (patient did not
progress or die)
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among those patients who had received previous rituximab
treatment, with an improved CR (30.0 vs 5.6%;
p = 0.093), ORR (45.0 vs 11.1%; p = 0.033), and median
PFS (5.4 vs 2.8 months; HR 0.52; 95% CI 0.26, 1.04) with
pixantrone versus comparator agents.
The results of the present analysis build on previous
results and suggest that it is possible to obtain a long-
lasting response with pixantrone. Also, the potential for a
durable response to pixantrone appears to be independent
of whether the best response to prior therapy was a CR, PR,
stable disease, or progressive disease. Of note, our results
indicate that it is possible to get a response with later lines
of NHL treatment, even with monotherapy, which is
important because monotherapy is typically associated
with lower rates of toxicities than multi-agent regimens.
Our observations are in line with those in a phase 2
study of pixantrone monotherapy in patients with relapsed,
aggressive NHL, in which several patients had very long
CRs that lasted more than 1 year [17]. In this study, two
female patients with stage II DLBCL and stage IV mantle
cell lymphoma experienced CRs lasting 17? and
15.2 months, respectively. This study also included one
patient (male; aged 66 years) with stage IV transformed
follicular lymphoma who experienced a PR lasting 24?
months.
There are several advantages of long-term responses in
this setting, where treatment options are limited. Treatment
is usually of palliative intent, and patients are often unable
to tolerate combination regimens because of factors
including comorbidities, age, poor performance status and
cardiotoxicity from previous anthracycline therapy [1].
Therefore, monotherapies with good tolerability and long-
term efficacy are sorely needed [1]. Pixantrone was
designed to maintain efficacy while reducing the risk of
cardiotoxicity. It is non-cross-resistant with anthracyclines
and generally well tolerated with a manageable toxicity
profile, making it a useful treatment option [13, 18].
Case studies have also indicated that pixantrone may be
useful in the routine clinic setting, as a bridge to autologous
SCT, or to induce a CR following relapse after allogenic
SCT [19, 20]. One patient with DLBCL achieved a CR
with third-line pixantrone monotherapy plus a single dose
of rituximab and benefited from long-term remission after
consolidation with high-dose chemotherapy and autologous
SCT [19]. Another patient with DLBCL who relapsed after
allogeneic SCT achieved a CR with pixantrone without any
considerable side effects [20].
Patients with long-term responses clearly have a tumor
that is chemosensitive to pixantrone. Intercalation of pix-
antrone into DNA results in successive rounds of aberrant
mitosis, ultimately leading to cell death [13]. In contrast to
anthracyclines, pixantrone is only a weak inhibitor of
topoisomerase II, and while it directly alkylates DNA,
forming stable DNA adducts and cross-strand breaks
[1, 11], the main way pixantrone causes cell death is to
impair the fidelity of mitosis without triggering the DNA
damage response or mitotic checkpoint activation. While it
is clear that pixantrone has a mechanism of action that is
unique from anthracyclines, the specific mechanisms
involved in the long-term responses seen among patients
receiving pixantrone in PIX301 are unknown.
Our study has several limitations. First, the descriptive
nature of the analysis is an obvious limitation, as is the
small sample size, which prevents firm conclusions from
being drawn. Additionally, there was no biopsy or positron
emission tomography (PET) scan performed at the time of
relapse and study entry for the clinical case presented in
Box 1, which is because PET scans and imaging were not
standard practice at the time of study entry. The clinical
case received etoposide and corticosteroids in the second
line, which could be regarded as an inadequate second-line
treatment, but this did not appear to negatively affect the
outcome.
5 Conclusion
Our observations imply that treatment with pixantrone
monotherapy in patients with multiply relapsed or refrac-
tory aggressive NHL who had received at least two prior
therapies can be associated with durable responses and
long-term remission. Our results suggest that a durable
response with pixantrone can be achieved irrespective of
the clinical response to last therapy, but this needs to be
confirmed in a larger number of patients.
Boxed Case Report
Box 1 Clinical case of long-term remission with
pixantrone
A 55-year-old male patient presented with enlarged
inguinal, para-iliac, and bronchopulmonary lymph nodes,
sweating and weight loss in November 2006. In Decem-
ber 2006, an inguinal lymph node biopsy was performed,
and histological and immunohistochemical findings
showed diffuse large B-cell lymphoma (DLBCL), stage
IIIB. By June 2007, the patient had achieved a partial
response (PR) after six cycles of CHOP as first-line
treatment. In December 2007, the patient presented with
enlarged inguinal and para-iliac lymph nodes, indicating
disease progression. The patient then received second-line
therapy with etoposide and corticosteroids. There was
further disease progression in January 2008. In February
2008, the patient signed an informed consent to partici-
pate in PIX301. Computed tomography (CT) assessment
revealed Ann Arbor stage III with enlarged
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